neurodegener initi buy
initi buy pt upsid pot next two
year transit early-stag neuro co interest
clinic program signific pot valu creation catalyst phase i/ii
inhibitor parkinson phase partner sni als/alzheim
importantli novel bbb blood-brain barrier pipelin platform technolog
clinic data ye
denali found core group key genentech scientist run neurolog
 group repres one interest next-gen neuro biolog compani
lot upsid pot time root eleg target neurolog
scienc go degeno-gen specif gene target play central role
seriou neurodegen diseas importantli de-risk neuro
compani focus util specif genet mutat guid target
pathway engag clear biomark strategi come onto investor
radar given recent posit updat last execut
get three program clinic land partner sni one advanc
novel bbb platform clinic could whole new angl upsid
stori advanc neuro get attent histor
perceiv early-stag neurodegener compani gener
perceiv high risk howev chang multipl neuro stori
work made investor money think investor continu
gravit data come program advanc investor get
confid neuro space
lot catalyst could move stock new phase i/ii data
come go-decis move inhibitor pivot phase ii/iii
make late-stag co year phase i/ii data sni
decis advanc al alzheim confirm commit pay
mileston bbb platform phase data new id enzym replac data
ye data look good alreadi could go elapras market current
sale shire/takeda would de-risk bbb platform add whole new
angl invest thesi given lower-risk tech could provid floor
downsid lastli potenti wave street enthusiasm neuro space depend
happen fda aducanumab decis mostli upsid
clear beneficiari fda amen differ bar huge
primari investor pushback high risk-high reward stori assumpt
area drug issu given focu novel target difficult diseas
parkinson alzheim question around next move sni control
decis make less en vogu target like comp
mid/lat stage neuro co jefferi bookrunn recent secondari offer
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
scenario parkinson id mp alzheim sblood-brain barrier/ technolog platform cash/ sharevaluationbear weightimpli market weightimpli market weightimpli market ascrib valu technolog platform management denali
end recent secondari offer
end recent secondari offer
base case base sum-of-the-
part sotp analysi dnli clinic candid
variou indic indic build
estim revenu cash flow stream
beyond probability-adjust dcf also ascrib
valu denali bbb technolog platform neurolog
expertis know-how estim cash
upsid scenario consid higher
probabl indic versu
base case scenario assum clinic
candid produc better expect result
on-going program garner signific share
larg market
downsid scenario
includ
estim cash per share plu reduc technolog
platform pipelin valu also ascrib lower
probabl program versu base case
base potenti safeti issu aris
inabl denali program meet key endpoint
studi
think share denali room appreci
back sever underappreci
catalyst pois derisk proprietari
pipelin technolog platform
neuroscientist believ give advantag
signific prior experi develop
blockbust drug expertis know-how
think pipelin less riski tradit
neurodegen program given focu human
biomark multipl shot goal
also novel blood-brain barrier platform
significantli improv drug deliveri
includ enzym replac drug
antibodi believ upcom bbb data
later year potenti unlock signific
valu
believ street lump neuro
focus compani ascrib typic
high risk pipelin
complet compound phase
ib studi select pot
advanc parkinson diseas
phase ib biomark data al
alzheim studi go/no-go decis
phase i/ii interim biomark data
etv id hunter syndrom pot late earli
import proof concept data
pleas see import disclosur inform page report
initi buy believ could see appreci stock next
month base number key data readout potenti advanc
program late-stag develop includ lead pivot phase ii/iii
bbb blood-brain barrier pivot phase ii next year inde
coupl year denali transit early-stag neurolog compani
three interest novel clinic program signific potenti valu
root eleg scienc target degeno-gen specif gene target
play central role neuro-degen diseas importantli de-risk
neuro compani focus util specif genet mutat guid
target pathway engag clear biomark strategi
inde appreci drug still rel high-risk vast
amount clinic efficaci data reli key differ opinion
compani market drug higher probabl success
consensu think uniqu insight human genet
underli biolog neuro-degen diseas
denali found core group key genentech scientist run neurolog
 group ultim repres one interest next-gen neuro biolog
compani lot upsid potenti time
specif co-found denali marc tessier-lavign chairman
current board member denali previous evp research cso
genentech
addit co-found ceo ryan watt director dept neurosci
genentech
schuth head neurosci partner genentech carol
ho vice-president earli clinic develop genentech cso zach sweeney
previous scientist team leader genentech
think sever catalyst could drive share higher
phase i/ii data come compani go-decis move
inhibitor pivot phase ii/iii make formal late-stag co year
phase i/ii data mid-year sni decis advanc al
alzheim confirm commit pay like mileston
bbb platform clinic phase data much better id enzym replac
get data ye data look good alreadi could go elapras market
current sale shire/takeda could de-risk bbb platform add
whole new angl invest thesi given lower-risk technolog could
provid floor downsid risk
lastli shall see potenti wave street enthusiasm neuro
space depend happen fda aducanumab alzheim
decis mostli upsid clear beneficiari fda amen
accept lower regulatori bar huge unmet need area
pleas see import disclosur inform page report
balanc sheet solid follow januari secondari offer
estim compani pro forma cash estim cash burn
next month compani move earlier stage clinic
candid larg clinic trial earli stage pipelin clinic henc
compani plenti cash go potenti see lot new data
support like advanc pipelin
bear neurolog particularli field neuro-degener diseas remain
one challeng area drug develop open question
whether target pathway biomark data translat signific clinic benefit
larg random clinic trial develop drug base degenogen
help allevi investor uncertainti link mutant gene toxic
protein subsequ patho-physiolog phenotyp degen diseas
complex exampl despit variou studi subset patient variou genet
popul amyloid-beta hypothesi alzheim diseas disappoint
remov pathogen amyloid beta plaqu clearli led improv cognit
benefit sever clinic studi date long-term safeti remain outstand
question small molecul program burn compani project
substanti increas come year highli like candid
variou mid/lat stage neuro compani may fit big pharma provid
nearer-term synergi commerci revenu growth high-scienc
technolog pipelin compani need play data first
pleas see import disclosur inform page report
base case base sum-of-the-part sotp analysi dnli
clinic candid variou indic indic build revenu
cash flow stream beyond probability-adjust dcf also
ascrib valu denali technolog platform/know-how estim cash end
upsid scenario consid higher probabl indic
versu base case scenario assum clinic candid produc better
expect result on-going program
downsid scenario cash per share
reduc technolog platform pipelin valu base potenti
safeti issu aris inabl denali program meet primari endpoint
key studi scenario denali clinic candid could gener unfavor
side effect properti delay prevent approv limit commerci opportun
result unfavor outcom clinic hold letter limit patient uptak
minim sale traction also ascrib lower probabl program versu
pleas see import disclosur inform page report
scenario parkinson id mp alzheim sblood-brain barrier/ technolog platform cash/ sharevaluationbear weightimpli market weightimpli market weightimpli market ascrib valu technolog platform management equiti research
genet basi program parkinson diseas could
inhibitor work famili idiopath parkinson diseas
lead wholly-own program
parkinson diseas base degenogen protein kinas
instrument lysosom activ -- process larg macromolecul
protein aggreg organel degrad mutat increas
activ product normal shown result lysosom
dysfunct genet caus famili parkinson diseas approxim
parkinson patient mutat hereditari origin exampl
googl co-found sergey brin publicli acknowledg written
key mutat data suggest chanc eventu
develop parkinson diseas due gradual deterior cell function
result lysosom dysfunct
normal activ partial inhibit via small molecul drug
believ restor normal lysosom function potenti amelior
neurodegener observ parkinson diseas
hallmark characterist famili idiopath parkinson diseas
accumul protein aggreg particularli alpha synuclein scientist believ
may explain part lysosom dysfunct inabl
aggreg effici degrad addit evid examin brain
therefor partial inhibit activ may benefici idiopath parkinson
diseas patient well help restor normal lysosom function clear
protein aggreg bolster point gwa genom wide associ studi
reveal mutat result reduc express function
protect parkinson diseas denali thu plan potenti phase
ii/iii program all-com parkinson patient well eventu studi
scientif rational behind inhibit alzheim al
could inhibitor work hereditari famili sporad alzheim
compani partner program al alzheim diseas
base degenogen function immedi downstream
compon tumor necrosi factor receptor signal cascad
activ signal pathway lead product pro-inflammatori
cytokin cell death gwa reveal mutat protein directli
upregul hyper-stimul activ underli caus case
famili al thu inhibit activ genet rational al
alzheim diseas rational inhibit come observ
rampant inflamm brain patient alzheim diseas
theoriz reduc inflamm may slow neurodegener observ
patient target problemat given structur
similar import protein neural regener given
pleas see import disclosur inform page report
key role signal inhibit could way dampen
addit opportun given inflamm signal pathway tnf sanofi
interrog peripher inhibitor could use treat auto-immun
diseas well
highli sought target due safeti
concern factor develop challeng investor
think potenti safeti issu liabil associ
sought target given clear link famili idiopath
parkinson diseas howev initi lung kidney morpholog chang observ
knockout ko mice mice non-human primat administ
inhibitor hamper continu develop recent consortium
scientist inhibitor candid merck genentech
demonstr morpholog chang occur anim administ
high dose drug importantli chang inconsequenti
impact lung kidney function revers inhibitor
remov denali complet long-term toxicolog studi multipl speci
shown result importantli denali receiv sign
fda short long-term human clinic studi inhibitor
suggest fda okay safeti inhibit
import mediat variou inflammatori process innat
adapt immun system inhibit activ long sought
potenti method modul inflamm partial inhibit reduc immun
activ decreas autoimmun diseas progress mous model howev
total loss function mice result increas suscept bacteri
infect moreov shown play protect role influenza
infect inflammatori breast cancer normal activ
necessarili knock preclin data suggest abl achiev within
reason therapeut window far long-term safeti go import
denali transport vehicl technolog platform get drug cross
blood-brain barrier compar similar program jcr pharma roch other
vehicl transport platform bring larg molecul antibodi across
blood-brain barrier bbb high effici base transferrin
receptor tfr tfr highli express bbb natur function bind
intern iron cell tfr highli express shuttl
side endotheli cell either side barrier intern
process co-opt transfer therapeut agent interest across blood-
brain barrier platform consist engin fc domain antibodi
singl tfr bind site fuse protein oligonucleotid interest
facilit effici transfer agent across bbb
importantli platform design improv upon address issu
observ transferrin base transport program compani
intrins effector immun activ function case
enzym replac type construct preserv immun activ may
pleas see import disclosur inform page report
inadvert consequ recruit and/or activ immun cell
denali remov intrins effector found fc domain construct
highlight jcr pharma technolog use backbon potent igg
antibodi depend cellular cytotox adcc may long term neg
effect case effector function need case antibodi
remov toxic aggreg capabl engin desir
level effector function
effici transcytosi effici transport macromolecul
blood brain use tfr releas macromolecul construct bind
affin avid due multival tfr high result construct
trap at/in cell bbb case earlier technolog
denali vehicl transport one moder affin bind site per fc domain
issu contrast question effici
roch brain shuttl technolog consist single-chain fab fragment link
antibodi interest period
denali wealth program early-stag pipelin denali like partner
program bring capit monet asset
convers manag express willing outlicens
unpartn program term accept compani
pipelin program unpartn think compani potenti partner
program base target think program could garner
high interest big pharma exampl atv syn alpha-synuclein could
interest larg pharma depend phase ii data look like releas
roche/prta
anticip partnership would similar denali jan takeda
sanofi deal compani provid denali up-front payment
signific develop mileston payment right co-develop/
investor think valuat catalyst path drive
support current stock price ascrib follow sum
part wholly-own program parkinson diseas use
assign po sale mutant pt
partnered-program sanofi alzheim al ascrib po
peak total sale cash technolog /manag valu
scenario incorpor valu mp ii could
put anoth way assum develop neuro drug use
multipl success cap would result pt assum
market cap chanc develop blockbust
multipl program pipelin
next month see share appreci toward pt sever
pleas see import disclosur inform page report
select potenti candid pivot studi think could
advanc phase ii/iii studi parkinson diseas mid first-
gen drug origin genentech alreadi shown posit result would
support advanc later stage trial think select day
inhibitor better drug properti happen also reduc
econom owe genentech would view posit street upcom
data pd patient look see inhibit activ
biomark demonstr potenc along clean safeti profil
 denali sanofi could advanc phase iib studi al and/or
alzheim diseas mid denali sanofi expect releas result
al alzheim diseas announc plan potenti move
later stage develop management state look clear target
pathway engag inhibit activ compani
develop sever proprietari biomark al ad howev given short
durat studi think unlik see signific chang
metric rather safeti target engag marker key move
mid-stag studi evalu clinic efficaci
 potenti posit interim result phase etv id mp ii
significantli derisk blood-brain barrier bbb vehicl technolog
program believ posit proof-of-concept data mp ii would
derisk mp ii program also derisk transport vehicl platform compani
state bar continu develop reduct gag think
achiev view program alreadi partial derisk data similar
tfr mediat bbb construct jcr pharma demonstr lower
reduct toxic gag
pleas see import disclosur inform page report
focus novel target strong genet rational neurodegen diseas thu de-risk otherwis inher difficult diseas area
stock pois upsid appreci sever import catalyst expect next month lot catalyst come look good
mani denali current program rapidli advanc late-stag pivot type studi target pathway engag establish phase i/ii
acceler clinic develop earli clinic trial focu clearli show target pathway engag achiev set threshold base
bbb platform realli valu stock given clinic data could extrem valuabl upsid pipelin play
fact data look good first program etv id year-end could significantli derisk entir platform unlock signific valu inde
data tfr bbb platform specif jcr pharma jcr cargo partial derisk approach
manag made ex-genentech scientist decad experi develop drug neurolog diseas
denali attract reach lucr collabor deal larg biotech/pharma compani alreadi includ sanofi takeda note denali maintain
signific right partnered-program co-commercialization/ co-develop opt-in right
two-third denali program remain unpartn could interest biotech/pharma
market opportun huge multipl shot goal seriou preval neurolog diseas parkinson diseas alzheim diseas
henc upsid potenti multi-fold
valuat rel high given earli stage natur program
gener develop drug space particularli hard rife clinic trial failur
remain seen whether target pursu ultim cognit benefit neurolog diseas
inhibit result morpholog chang lung renal cell current result suggest chang revers upon cessat drug
function inconsequenti remain seen whether case longer larger clinic trial
identif patient clinic trial real world could challeng test mutat current standard practic
rational inhibit idiopath parkinson diseas weaker vs famili parkinson diseas
tfr express tissu outsid brain unclear whether could issu
other includ roch jcr pharma develop technolog platform help protein macromolecul cross blood-brain barrier
elapras market exclus expir thu etv id clinic drug show clear cognit benefit justifi rare diseas price adopt
import mediat immun system theoret inhibit activ may result increas infect cancer
pleas see import disclosur inform page report
pleas see import disclosur inform page report
companytickerratingpric targetpricedrugdrug lead indicationstagemarket cap enterpris valu vaccinephas denali dementiaphas iiphas edita congenitalamaurosi aphas intellia transthyretin prevail voyag vy-aadcparkinson sphase estim cash balanc post recent follow-onspr equiti research
denali biopharmaceut compani focus develop medicin
treatment alzheim diseas parkinson diseas amyotroph later sclerosi al
neurodegen diseas aim denali focus three pillar
focus target neurodegener link underli genet mutat
degenogen util proprietari blood-brain barrier bbb technolog guid
develop base clear target pathway engag biomark activ
denali lead wholly-own program parkinson diseas
current phase ib studi addit clinic data candid select
phase ii/iii trial expect mid
sanofi-partn program current phase studi
alzheim diseas al peripher diseas data expect mid
base data denali sanofi expect make go-no-go decis
continu develop indic
mp ii denali lead program use blood-brain barrier bbb technolog
platform expect initi proof-of-concept data sever
addit bbb program current preclin develop
pleas see import disclosur inform page report
timeexpect newsflowprogramindicationmid ib data final candid mid ib data i/ii data mp idsmp result phase ii/iii phase ii/iii mp idsmp ii exhibit pipelin tabl
pleas see import disclosur inform page report
programtargetstageindicationcorp ibparkinson ibparkinson ibmp ii hunter dementiatakedaatv asynalpha-synucleinpreclinicalparkinson msa-etv sgshsulfamidasepreclinicalmp iiia sanfilippo phase ialzheim al ial peripher phase ira peripher preclinicalcrohn function pathwaycellular homeostasisothergli biolog pathway equiti research
parkinson diseas
grow number genet mutat found diseas
caus famili patient risk-conf lead increas risk idiopath
parkinson diseas pd patient mani mutat link pd
smaller set mutat found diseas caus risk-conf
link underli biolog lead logic rational scientif drive
leucine-rich repeat kinas kinas thought import
mainten multipl cellular process includ lysosom function
mutat shown increas activ lead hyper-
phosphoryl rab appear neg modul lysosom function
disrupt lysosom function central pathophysiolog pd result
accumul protein neuron cell ultim result cell death neuro-
hallmark cellular patholog pd accumul protein aggreg name
gain-of-funct genet mutat one common genet
caus famili pd around parkinson hereditari mutat
patient probabl age depend develop parkinson
addit non hereditari sporad mutat found along
gene idiopath parkinson well reason inhibitor could work
hereditari idiopath form diseas
preclin model pd inhibit restor normal lysosom function
administr inhibitor cell express mutat result
dose-depend correct lysosom morpholog function determin
exhibit inhibit thought restor normal
lysosom function digest protein aggreg normal
pleas see import disclosur inform page report
inhibitor parkinson diseas
recent report posit result program parkinson
diseas neg regul lysosom function gain-of-function/act
mutat one common causal risk factor pd inhibit
hypothes restor lysosom function prevent neuron cell death
lead asset demonstr robust engag target pathway
gener safeti toler patient parkinson diseas second
asset target demonstr biomark engag safeti toler
healthi volunt expect report biomark data parkinson diseas patient
base data make select go-
forward drug phase ii/iii clinic trial parkinson diseas
know
demonstr target pathway engag pd patient
target pathway engag hv translat similar result pd
patient find bode well upcom result
benefit inhibit improv lysosom marker
pronounc carrier pt bode well propos moa
know still cautiou
gener safe well toler phase ib studi name
headach increas stand hear rate watch longer
larger studi
biomark data deriv blood urin thu unclear occur
peripheri also occur small portion brain impact
on-going phase ib daili inhibitor data mid
expect line
thirty-four treatment experienc naiv pd patient expect random
one four arm
patient dose day high dose mid dose low
dose placebo daili inhibitor
note protocol recent chang add higher dose cohort studi
endpoint studi target engag blood/pbmc
chang lysosom biomark csf urin
symptom scale quantit gait assess
pleas see import disclosur inform page report
result studi expect mid base result
select continu clinic develop
phase ii/iii plan inhibitor rapid advanc potenti
follow select clinic develop
initi phase ii/iii studi treatment naiv pd patient second phase
ii/iii treatment naiv patient idiopath pd primari endpoint studi
mds-updr standard endpoint parkinson diseas studi assess
symptom pd
recent releas phase ib twice daili inhibitor robust
reduct inhibit biomark
thirti treatment experienc naiv pd patient sporad w/ mutat
random one three arm twenty-eight patient complet studi
patient dose day high dose low dose
placebo twice daili inhibitor
endpoint studi target engag blood/pbmc
chang lysosom biomark csf urin
symptom scale quantit gait assess
recent report met biomark endpoint phase ib studi
inhibitor kinas protein target
immedi downstream target blood dose test
improv lysosom biomark bmp urin low high
dose respect note bmp marker lysosom dysfunct reduct
biomark well-establish effect inhibit
knowledg data releas exploratori endpoint measur
would surpris chang endpoint observ short
exhibit demonstr robust target pathway engag
inhibit lysosom function
pleas see import disclosur inform page report
profil lysosom marker mutat patient reveal
accumul certain lysosom biomark csf patient
benefit inhibit pronounc carrier
patient orang dot bode well propos moa
note sporad pd patient grey dot also show reduct lysosom
biomark par patient
exhibit inhibit reduces lysosom biomark carrier sporad pd pt
safeti toler
dose gener well toler common
headach nausea
one case legionella pneumonia consid unrel studi
drug infect someth need watch given high express
immun cell role lysosom function import remov
show higher incid moder one sever headach lead dose
reduct nausea/headach result earli withdraw
note across studi manag revers
compani also note chang pulmonari function anoth import
paramet watch given preclin data show potenti perturb
lung kidney morpholog
two pt increas heart rate dose depend effect supin
stand vital sign note
pleas see import disclosur inform page report
also note trend toward mild increas creatinin still within normal
recent releas phase result robust pathway
engag hv
healthi volunt administ multipl ascend dose
note protocol recent chang add higher dose cohort studi
healthi volunt shown target pathway engag
reduc lysosom function
note healthi volunt appear less effect reduc
biomark hv compar
anticip result healthi volunt recapitul parkinson
safeti toler
gener well toler major ae mild
sae discontinu relat drug report
exhibit demonstr pathway engag reduc lysosom function hv
phase
complet phase studi healthi volunt
six activ single-ascend dose cohort per cohort dose
eight activ multiple-ascend dose cohort per cohort dose
mg qd/bid mg bid day period
pleas see import disclosur inform page report
